SOCMA updates advocacy against IST provisions
The US Society for Chemical Manufacturers and Affiliates (SOCMA) has provided an update of its efforts regarding the recently passed US Chemical and Water Security Act of 2009 (HR 2868), which includes inherently safer technology (IST) requirements that SOCMA opposes.
The US Society for Chemical Manufacturers and Affiliates (SOCMA) has provided an update of its efforts regarding the recently passed US Chemical and Water Security Act of 2009 (HR 2868), which includes inherently safer technology (IST) requirements that SOCMA opposes.
Although SOCMA favors chemical site-security provisions, it opposes mandated IST requirements. IST is a conceptual framework that covers chemical processing procedures, equipment, protection and when feasible, the use of safer substances.
“The IST provisions in the bill were approved despite numerous attempts by lawmakers to improve the bill and with little regard to previous testimony by experts from academia, process safety organizations and industry who all opposed an IST mandate. Until last month, the Department of Homeland Security also long-opposed mandatory IST implementation before abruptly switching its position in time for a House subcommittee hearing,” said SOCMA in a press release following the passage of the legislation.
SOCMA reported that although the bill was recently passed by the House, its advocacy program, SOCMA CONNECT, conducted extensive advocacy to urge lawmakers to vote against the bill. The bill now goes to the Senate for consideration.
“We look forward to working with the Senate, which we expect will be more willing to work with all stakeholders than the House committees that moved the IST provisions through the chamber,” said Bill Allmond, vice-president of government relations and ChemStewards at SOCMA, in the press release.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Your Ultimate Guide for CMC Testing Support for Gene and Cell Therapy
November 21st 2024Explore the complexities of gene and cell therapy development with our comprehensive guide to Chemistry, Manufacturing, and Controls (CMC) testing. Learn how our expertise ensures the safety, potency, and quality of advanced therapies, supporting your journey from product development through regulatory approval.
